Dong-E Ejiao's 2025 Performance Shows Steady Growth, R&D Innovation Leads Time-Honored Brand's High-Quality Transformation

On March 20, Dong-E E Jiao disclosed its 2025 annual performance report. The company achieved total revenue of 6.7 billion yuan, a year-on-year increase of 13.17% after excluding accounting restatement effects; net profit attributable to shareholders of 1.739 billion yuan, up 11.67% year-on-year; and a net cash flow from operating activities of 2.289 billion yuan.

Data from the annual report shows that in 2025, Dong-E E Jiao significantly increased its R&D investment, with R&D expenses reaching 272 million yuan, a 56.8% increase year-on-year, far exceeding the growth rate of revenue and profit, demonstrating the company’s commitment to making technological innovation its core development driver. In terms of R&D platform development, the company was approved as a national enterprise technology center, established a dual-academician workstation, and hosted a high-profile science and technology innovation conference, gathering three Chinese Academy of Engineering academicians and over a hundred industry experts, creating a rare advanced R&D matrix in the traditional Chinese medicine industry.

In core technology R&D, Dong-E E Jiao achieved several milestone breakthroughs. In evidence-based medicine, its research on “Fufang Ejiao Jiang for Cancer-Related Fatigue” has consecutively won international awards such as ASCO and SIO, gaining recognition for TCM efficacy from the mainstream international medical community. Notably, Dong-E E Jiao identified a new blood-activating peptide from the main components of Ejiao for the first time, with related results published in the international journal Collagen and Leather, scientifically revealing the blood-nourishing mechanism of Ejiao and providing scientific endorsement for the product.

The成果 of R&D innovation has also been transformed into driving force for business development. Dong-E E Jiao has established a new growth pattern driven by both “medicine + health consumer products.” On the pharmaceutical side, the Fufang Ejiao Jiang, based on evidence-based research, continues to expand in clinical fields such as cancer-related fatigue, opening up broader medical market space; on the consumer products side, leveraging technological breakthroughs in enzyme hydrolysis and formulation innovation, the company launched new products such as “Little Gold Bar” Ejiao instant powder, Royal Enclosure 1619, and “Zhuang Ben” Cistanche, precisely meeting the convenience health needs of young consumers. This not only enriches the product matrix but also promotes brand youthfulness and accelerates the formation of the company’s second growth curve.

While maintaining steady growth in performance, Dong-E E Jiao continues to optimize its shareholder return system and release development confidence through multiple measures. The company maintains a high dividend payout tradition, planning to distribute 14.31 yuan (including tax) per 10 shares in 2025, totaling 922 million yuan in dividends, with a cumulative mid-term dividend of 1.74 billion yuan for the year. Since listing, the company has paid dividends 29 times, totaling over 11 billion yuan. As a “cash cow” with continuous 100% dividend payout for many years, the company also launched new capital market initiatives in 2025, including the first stock incentive plan since listing in July, granting 958,739 restricted shares to 172 core employees to align long-term interests; additionally, at year-end, it initiated a share repurchase and cancellation plan of 100 million to 200 million yuan, forming a “dual reward” strategy of high dividends plus buyback and cancellation, effectively enhancing earnings per share and return on equity, marking the company’s official transformation into a “value manager” in the capital market.

Currently, with a series of domestic consumption stimulus policies, relatively relaxed medical insurance and centralized procurement policies, the traditional Chinese medicine industry is entering a policy dividend period. As an industry leader, Dong-E E Jiao leverages its strong brand foundation, comprehensive product matrix, continuously optimized channel layout, and the ecological empowerment of China Resources Group, gaining significant first-mover advantages amid the consumption recovery wave.